The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen

Expert Opinion on Biological Therapy

Volumn 2, Issue 1, 2002, Pages 75-85

  Bramson, Jonathan L ^a   Wan, Yong Hong ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Adenovirus; Antigen; Cancer; Dendritic cell; Infectious disease; MHC class I; MHC class II; Plasmid DNA; Vaccine; Vaccinia virus

Indexed keywords

ANTIGEN; GENETIC VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLASMID DNA; UNCLASSIFIED DRUG; VACCINE; VACCINIA VACCINE; DNA VACCINE;

ANTIGEN PRESENTATION; ANTIGEN STRUCTURE; CANCER PREVENTION; CELL COMPARTMENTALIZATION; COMPARATIVE STUDY; DENDRITIC CELL; DRUG EFFICACY; EXPRESSION VECTOR; GENETIC CODE; IMMUNE RESPONSE; IMMUNOGENICITY; OPEN READING FRAME; PATHOGENESIS; REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VACCINATION; VIRUS INFECTION; ANIMAL; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY;

ADENOVIRIDAE; VACCINIA VIRUS; VECTORS;

ANIMALS; ANTIGENS; GENETIC VECTORS; HUMANS; VACCINATION; VACCINES, DNA;

EID: 0035989708     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.1.75     Document Type: Review

References (101)

1. CpG DNA switches on Th1 immunity and modulates antigen-presenting cell function
2. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages
3. Functional genomics of Neisseria meningitidis pathogenesis
4. Signature-tagged mutagenesis in the identification of virulence genes in pathogens
5. DNA and RNA-based vaccines: Principles, progress and prospects
6. Genetically modified viruses: Vaccines by design
7. Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors
8. Listeria monocyrogenes: A potent vaccine vector for neoplastic and infectious disease
9. DNA vaccines: Immunology, application, and optimization
10. Nonviral vectors in the new millennium: Delivery barriers in gene transfer
11. Adenovirus vectors for gene delivery
12. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
13. The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses
14. Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant
15. Applications of pox virus vectors to vaccination: An update
16. Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants
17. Adenoviruses as vectors for delivering vaccines to mucosal surfaces
18. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity
19. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization
20. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts
21. Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA
22. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
23. Dendritic cells and the control of immunity
24. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium
25. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
26. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells
27. RNA transfected dendritic cells as cancer vaccines
28. Viral vectors for gene transfer into antigen presenting cells
29. Dendritic cell-derived IL-12 is not required for the generation of cytotoxic, IFN-gamma-secreting, CD8+ CTL in vivo
30. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: Implications for cancer vaccines
31. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells
32. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination
33. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells
34. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity
35. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
36. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism
37. Multiple paths for activation of naive CD8(+) T cells: CD4-independent help
38. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: Implications for the clinical use of dendritic cells
39. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
40. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
41. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
42. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge
43. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
44. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus
45. Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis
46. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
47. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
48. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
49. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
50. The prime-boost strategy: Exciting prospects for improved vaccination
51. Suppression of host immune response by the core protein of hepatitis C virus: Possible implications for hepatitis C virus persistence
52. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination
53. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses
54. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity
55. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus
56. DNA immunization with minigenes: Low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination
57. A recombinant minigene vaccine containing a nonameric cytotoxic-T-lymphocyte epitope confers limited protection against Listeria monocytogenes infection
58. The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA
59. Cytotoxic T cell responses to DNA vaccination: Dependence on antigen presentation via class II MHC
60. Antigen processing in vivo and the elicitation of primary CTL responses
61. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes
62. Protection by minigenes: A novel approach of DNA vaccines
63. A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen
64. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine
65. Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes
66. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines
67. Degradation of cell proteins and the generation of MHC class I-presented peptides
68. The ubiquitin-mediated proteolytic pathway: Mode of action and clinical implications
69. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization
70. DNA immunization: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction
71. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes
72. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens
73. An autologous oral DNA vaccine protects against murine melanoma
74. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic encloplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide
75. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes
76. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope
77. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen
78. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
79. Immunology. Licence to kill
80. MHC class II-restricted presentation of intracellular antigen
81. Class II MHC molecules can use the endogenous pathway of antigen presentation
82. A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses
83. Expression of endogenous peptide pepticle-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins
84. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens
85. Characterization of MHC class II-presented peptides generated from an antigen targeted to different endocytic compartments
86. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments
87. Targeting human papillomavirus papillornavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors
88. Targeting a polyepitope protein incorporating multiple class II- restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: A novel approach to vaccine design
89. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide
90. Heteroclitic immunization induces tumor immunity
91. gpl00/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
92. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue
93. A new era for cancer immunotherapy based on the genes that encode cancer antigens
94. Coupling and uncoupling of tumor immunity and autoimmunity
95. Genetic immunization of mice with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma
96. Tumor immunity and autoimmunity induced by immunization with homologous DNA
97. The central role of CD4(+) T cells in the antitumor immune response
98. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
99. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
100. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene
101. Cytokine regulation of host defense against parasitic gastrointestinal nematodes: Lessons from studies with rodent models